Trial Profile
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (12.5 mg, 50 mg, 200 mg) of BI 135585 XX (Tablet) in Chinese and Japanese Healthy Male Volunteers (Randomised, Double-blind,Placebo-controlled Within Dose Groups).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2013
Price :
$35
*
At a glance
- Drugs BI 135585 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 04 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 14 Feb 2011 New trial record